Workshop on immunogenicity assessment of biotechnology-derived therapeutic proteins

Date: 09/03/2016
Location: European Medicines Agency, London, UK

The workshop is held to discuss the draft Committee for Medicinal Products for Human Use/Biosimilar Medicinal Products Working Party (BMWP) guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Participants will include experts from the BMWP, the Biostatistics Working Party (BWP), other regulatory authorities and stakeholders who provided comments on the draft guideline as well as specifically invited interested parties.

Documents

Multimedia

How useful was this page?

Add your rating